Loading the company…
Loading the company…
Families: Coronary intervention (PCI), Tumor & fibroid embolization.
All companies · Product and company coverage
In the last ten years FDA made 19 decisions for Celonova Biosciences (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 2 procedure families, the most in 2019 (9). The latest was on 2021-10-12.
| Family | Decisions on record |
|---|---|
| Coronary intervention (PCI) | 19 |
| Tumor & fibroid embolization | 4 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2021-10-12 | PMA | P160014-S018 | COBRA PzF NanoCoated Coronary Stent System · Labeling Change - PAS |
| 2020-11-19 | PMA | P160014-S017 | COBRA PzF NanoCoated Coronary Stent System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2020-06-18 | PMA | P160014-S015 | COBRA PzF NanoCoated Coronary Stent System · Change Design/Components/Specifications/Material |
| 2020-04-27 | PMA | P160014-S016 | COBRA PzF NanoCoated Coronary Stent System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2020-03-29 | PMA | P160014-S010 | COBRA PzF NanoCoated Coronary Stent System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Celonova Biosciences.